BSBR vs. UBS: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2249240/bsbr-vs-ubs-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2249240
Apr 02, 2024 - BSBR vs. UBS: Which Stock Is the Better Value Option?
0
UBS Group's (UBS) JV to Buy CS' Japanese Wealth Management Unit
https://www.zacks.com/stock/news/2252187/ubs-group-s-ubs-jv-to-buy-cs-japanese-wealth-management-unit?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2252187
Apr 08, 2024 - UBS Group's (UBS) JV is set to acquire Credit Suisse's wealth management unit in Japan. Per the deal, Credit Suisse's advisors and wealth management assets are set to be transferred to the JV.
0
UBS Group (UBS) to Swap Stake in CS Securities in China
https://www.zacks.com/stock/news/2252802/ubs-group-ubs-to-swap-stake-in-cs-securities-in-china?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2252802
Apr 09, 2024 - UBS Group (UBS) is seeking to swap its holding in Credit Suisse Securities in order to gain the complete ownership of its joint venture UBS Securities in China.
0
UBS sees earnings heading for strongest pace of quarterly growth in more than 2 years
https://seekingalpha.com/news/4093721-ubs-sees-q1-earnings-heading-for-strongest-pace-of-growth-in-more-than-2-years?source=feed_sector_healthcare
Apr 24, 2024 - UBS sees corporate earnings heading toward biggest quarterly growth rate since 2021. Read more here.
0
UBS Q4 Earnings Decline Y/Y on Higher Expenses, Revenues Up
https://www.zacks.com/stock/news/2222803/ubs-q4-earnings-decline-y-y-on-higher-expenses-revenues-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2222803
Feb 07, 2024 - A rise in operating expenses hinders UBS' Q4 earnings. Though the Business divisions' performances have not been so impressive, it managed to report higher revenues.
0
UBS starts Axsome at buy, sees Auvelity hitting $1B sales by 2030
https://seekingalpha.com/news/4064942-ubs-starts-axsome-at-buy-sees-auvelity-hitting-1b-sales-by-2030?source=feed_sector_healthcare
Feb 08, 2024 - UBS has initiated coverage of Axsome Therapeutics (AXSM) with a buy rating, commenting that it was bullish on the launch of the company’s drug Auvelity and upco
0
Nvidia: UBS Note Should Raise Alarms
https://seekingalpha.com/article/4670524-nvidia-ubs-note-should-raise-alarms?source=feed
Feb 15, 2024 - UBS raises Nvidia's (NVDA) earnings estimates and price target, but warns of near-term trouble for growth due to decreased lead times. Learn why it is posing a risk for investors.
0
Alkermes downgraded at UBS as stock nears 52-week high
https://seekingalpha.com/news/4069051-alkermes-downgraded-ubs-stock-nears-52-week-high?source=feed_sector_healthcare
Feb 20, 2024 - UBS downgrades Alkermes to sell due to disappointing sales and negative pipeline update. Read more here.
0
UBS Group (UBS) Seeks Wealth Management Growth in the US
https://www.zacks.com/stock/news/2242415/ubs-group-ubs-seeks-wealth-management-growth-in-the-us?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2242415
Mar 18, 2024 - UBS Group (UBS) seeks merger and acquisition opportunities in the United States to expand its wealth management footprint in the country.
0
UBS Group (UBS) to Undergo Two Stress Tests in '24 by FINMA
https://www.zacks.com/stock/news/2245113/ubs-group-ubs-to-undergo-two-stress-tests-in-24-by-finma?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2245113
Mar 22, 2024 - Amid heightening concerns over its increased balance sheet, UBS Group (UBS) is subjected to two stress tests this year along with around 40 reviews by FINMA.
0
<Page 2